title: Single perioperative dose of tranexamic acid in primary hip and knee arthroplasty.
abstract: BACKGROUND
  Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin. It has been shown to reduce blood loss in trauma and other haemorrhagic conditions and has recently been utilised in elective orthopaedic surgery. There are various methods of administering TXA described in the literature.
  
  
  METHODS
  This retrospective cohort study reviews the effects of a single perioperative 1 g intravenous bolus on patients undergoing primary hip and knee arthroplasty and its effect on operative blood loss. After excluding patients who did not fulfil our inclusion criteria, a total of 110 patients were included in this study. Fifty underwent primary hip arthroplasty (30 treated with TXA; 60.0 %), and 60 underwent primary knee arthroplasty (29 treated with TXA; 48.3 %). The main outcome measure was red cell volume and total blood loss, and secondary measures were needed for blood transfusions, presence of thromboembolic events, and length of hospital stay.
  
  
  RESULTS
  Both cohorts who received TXA showed a reduction in immediate postoperative red cell volume loss and total blood loss (p < 0.01). There was no association with the administration of TXA and the rate of postoperative blood transfusions (hip p = 0.36, knee p = 0.13), incidence of symptomatic deep vein thrombosis (hip p = 0.36, knee p = 0.31), or postoperative hospital length of stay (hip p = 0.70, knee p = 0.68).
  
  
  CONCLUSIONS
  This study demonstrates that a single perioperative bolus of intravenous TXA may significantly reduce operative blood loss in both primary total hip and knee arthroplasty in a cost-effective manner, in combination with meticulous perioperative haemostasis.
authors.affiliation: Department of Trauma and Orthopaedics, Barnet Hospital, Wellhouse Lane, Barnet, EN5 3DJ, UK, davidgeorge@doctors.org.uk.
authors.forename: D A
authors.initials: DA
authors.lastname: George
authors.forename: K M
authors.initials: KM
authors.lastname: Sarraf
authors.forename: H
authors.initials: H
authors.lastname: Nwaboku
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000933:Antifibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects / Q000379:methods*; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects / Q000379:methods*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion; D001810:Blood Volume; D004911:Erythrocyte Volume / Q000187:drug effects; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D019990:Perioperative Care; D012189:Retrospective Studies; D014148:Tranexamic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D020246:Venous Thrombosis / Q000139:chemically induced
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid
references.citation: J Bone Joint Surg Br. 2011 Jan;93(1):39-46
references.pmid: 21196541
references.citation: Spine (Phila Pa 1976). 2008 Nov 15;33(24):2577-80
references.pmid: 19011538
references.citation: J Bone Joint Surg Am. 2010 Nov 3;92(15):2503-13
references.pmid: 21048170
references.citation: Lancet. 2010 Jul 3;376(9734):23-32
references.pmid: 20554319
references.citation: Cost Eff Resour Alloc. 2010 Feb 17;8(1):1
references.pmid: 20163726
references.citation: J Arthroplasty. 2012 Dec;27(10):1838-43
references.pmid: 22704229
references.citation: Int Orthop. 2004 Apr;28(2):69-73
references.pmid: 15224162
references.citation: PLoS One. 2011 May 03;6(5):e18987
references.pmid: 21559279
references.citation: Biochemistry. 1999 Nov 30;38(48):15741-55
references.pmid: 10625440
references.citation: Cochrane Database Syst Rev. 2007 Oct 17;(4):CD001886
references.pmid: 17943760
references.citation: Clin Orthop Relat Res. 2010 Jul;468(7):1905-11
references.pmid: 20063079
references.citation: Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004896
references.pmid: 21249666
references.citation: J Bone Joint Surg Br. 2001 Jul;83(5):702-5
references.pmid: 11476309
references.citation: Hip Int. 2013 Jan-Feb;23(1):72-9
references.pmid: 23397201
references.citation: BMJ. 2012 May 17;344:e3054
references.pmid: 22611164
references.citation: Anesthesiology. 1995 Feb;82(2):383-92
references.pmid: 7856897
references.citation: Acta Orthop Scand. 2000 Jun;71(3):250-4
references.pmid: 10919295
references.citation: Semin Thromb Hemost. 1997;23(6):493-501
references.pmid: 9469621
references.citation: Surgery. 1962 Feb;51(2):224-32
references.pmid: 21936146
references.citation: J Arthroplasty. 2011 Jan;26(1):24-8
references.pmid: 20171048
references.citation: Acta Chir Belg. 2007 Jul-Aug;107(4):397-401
references.pmid: 17966532